Skip to main content

Table 4 Prevalence of mutations in pfcrt, pfmdr1, pfdhfr and pfdhps in pre-treatment and post-treatment samples

From: Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania

Position (N) Mutants (n) Percentage P-value
Pfcrt 76    
Pre-treatment (90) 10 11.1  
Post-treatment (12) 4 33.3 0.22
Pfmdr1 86    
Pre-treatment (95) 6 6.3  
Post-treatment (19) 8 42.1 0.0000
Pfdhfr 108    
Pre-treatment (97) 92 94.8  
Post-treatment (29) 21 74.2 0.0009
Pfdhfr 51    
Pre-treatment (97) 73 75.3  
Post-treatment (29) 20 69.0 0.025
Pfdhfr 59    
Pre-treatment (97) 80 82.5  
Post-treatment (29) 15 51.7 0.0000
Pfdhps 437 (N)    
Pre-treatment (96) 71 74  
Post-treatment (21) 7 33.3 0.0003
Pfdhps 540    
Pre-treatment (95) 66 69.5  
Post-treatment (21) 8 38.1 0.0000